Severity of COVID-19 and Vitamin D Supplementation

Launched by FEDERAL STATE BUDGETARY INSTITUTION, V. A. ALMAZOV FEDERAL NORTH-WEST MEDICAL RESEARCH CENTRE, OF THE MINISTRY OF HEALTH · Dec 20, 2021

Keywords

ClinConnect Summary

The COVID-19 pandemic that swept the world in 2019 radically changed not only the social sphere of life, subordinating everything around to its influence, but also the healthcare sector. It affected both its practical and scientific sides, globally changing the approach to medicine. Numerous studies around the globe are being conducted on the prevention and treatment of this infection. A significant amount of them study the role of vitamin D in the pathogenesis of the disease. Cholecalciferol (Vitamin D) is a fat-soluble vitamin that is involved in maintaining the serum calcium-phosphorus g...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • males and females aged 18 to 75 years
• • who did not take Vitamin D supplementation
• • COVID-19 clinical features
• • signed informed consent to participate in the research.
• Exclusion Criteria:
• • pregnancy or nursing
• • primary hyperparathyroidism or hypercalcemia other etiologies (including 24-hydroxylase mutation)
• • a history of granulomatous diseases
• • severe gastrointestinal diseases (clinically apparent malabsorption syndrome)
• • liver disease
• • kidney disease
• • individual intolerance drug
• • vitamin D supplementation in a dose of more than 800 IU per
• • drugs known to affect vitamin D metabolism (e.g., anticonvulsants, glucocorticoids, diuretics)
• • alcohol and drug addiction.
• • history of cancer (less than 5 years)